ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 15, 2021. The filing serves to announce the company's financial results for the quarter ended September 30, 2021, via a press release furnished as Exhibit 99.1. The company is classified as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release (Exhibit 99.1) but are not included in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It solely references the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 15, 2021) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to the company's product development pipeline or regulatory milestones mentioned in the press release.
- Check for any new debt obligations or equity financing activities disclosed in the full results.